Related references
Note: Only part of the references are listed.Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy
S. A. Scott et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events A Systematic Review and Meta-analysis
Michael V. Holmes et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Pharmacogenomics and Clopidogrel Irrational Exuberance?
Steven E. Nissen
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI A Meta-analysis
Jessica L. Mega et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration A Systematic Meta-Analysis
Jean-Sebastien Hulot et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
Guillaume Pare et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
Alan R. Shuldiner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Jean-Sebastien Hulot et al.
BLOOD (2006)